title: Standard medical management in secondary prevention of ischemic stroke in China (SMART).
abstract: BACKGROUND
  Although guidelines for secondary ischemic stroke have been developed, there is a gap between guidelines and clinic practice.
  
  
  OBJECTIVE
  This study will investigate the current status of secondary ischemic stroke prevention in China, and implement a standard medical program in ischemic stroke and/or transient ischemic attack patients, and to examine the feasibility and efficacy of the program.
  
  
  METHODS
  This is a multicentre, parallel, randomized, open label, controlled trial to evaluate the feasibility and efficacy of a recommended guideline based program (SMART) in secondary stroke prevention. Forty-eight sites across Mainland China will participate in the trial. The number of enrolled patients in the study will be 4074. Primary outcome includes the proportion of patients adherent to eligible measures recommend by the SMART program, which is derived from current prevention guidelines for ischemic stroke, and the proportion of the patients achieving the treatment target. Secondary outcomes include new onset ischemic stroke, hemorrhagic stroke, acute coronary syndrome and all causes of death. The study has been registered on Clinicaltrials.gov (NCT00664846); to date, 3380 patients have been enrolled.
authors.affiliation: Department of Neurology, Peking Union Medical College Hospital, Beijing, China.
authors.forename: Bin
authors.initials: B
authors.lastname: Peng
authors.forename: Yicheng
authors.initials: Y
authors.lastname: Zhu
authors.forename: Liying
authors.initials: L
authors.lastname: Cui
authors.forename: Jun
authors.initials: J
authors.lastname: Ni
authors.forename: Weihai
authors.initials: W
authors.lastname: Xu
authors.forename: Lixin
authors.initials: L
authors.lastname: Zhou
authors.forename: Ming
authors.initials: M
authors.lastname: Yao
authors.forename: Lin
authors.initials: L
authors.lastname: Chen
authors.forename: Jianming
authors.initials: J
authors.lastname: Wang
authors.forename: Yongjun
authors.initials: Y
authors.lastname: Wang
authors.forename: Chuanqiang
authors.initials: C
authors.lastname: Pu
mesh_terms: D054058:Acute Coronary Syndrome / Q000453:epidemiology / Q000517:prevention & control; D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use*; D002545:Brain Ischemia / Q000145:classification / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control*; D002423:Cause of Death; D002543:Cerebral Hemorrhage / Q000453:epidemiology / Q000517:prevention & control; D002681:China / Q000453:epidemiology; D019468:Disease Management; D005240:Feasibility Studies; D019983:Guideline Adherence; D006801:Humans; D020766:Intracranial Embolism / Q000453:epidemiology / Q000517:prevention & control; D008875:Middle Aged; D018579:Patient Selection; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D012107:Research Design; D012307:Risk Factors; D055502:Secondary Prevention / Q000458:organization & administration*; D020521:Stroke / Q000145:classification / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control*; D055815:Young Adult
chemical_list: D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors